Key Takeaways Resmed's Q1 adjusted EPS rose 15.9% to $2.55, beating estimates on stronger sales growth.RMD's revenues climbed 9.1% to $1.34 billion, led by gains in Sleep and Breathing Health products.RMD's gross margin expanded 285 bps to 62%, with the adjusted operating margin improving to 36.1%.Resmed Inc.’s (RMD) adjusted earnings per share (EPS) in the first quarter of fiscal 2026 were $2.55, up 15.9% year over year. The metric beat the Zacks Consensus Estimate by 2.41%.The adjustments include certain ...